Opus Genetics (IRD) Operating Expenses (2010 - 2026)

Opus Genetics (IRD) has 17 years of Operating Expenses data on file, last reported at $16.5 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $16.5 million, up 15.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.0 million (down 29.42% YoY), and the FY2025 annual result was $52.8 million, down 27.74% from the prior year.
• Operating Expenses grew to $16.5 million in Q1 2026 per IRD's latest filing, from $15.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $42.3 million in Q4 2024 and troughed at $4.5 million in Q3 2022.
• A 5-year average of $11.4 million and a median of $9.4 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses soared 494.54% in 2024, then slumped 63.81% in 2025.
• A 5-year view of Operating Expenses shows it stood at $5.6 million in 2022, then rose by 26.24% to $7.1 million in 2023, then soared by 494.54% to $42.3 million in 2024, then plunged by 63.81% to $15.3 million in 2025, then grew by 7.85% to $16.5 million in 2026.
• Business Quant data shows IRD's Operating Expenses at $16.5 million in Q1 2026, $15.3 million in Q4 2025, and $11.4 million in Q3 2025.